These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25358680)

  • 61. Peripheral biomarkers of Alzheimer's disease.
    Khan TK; Alkon DL
    J Alzheimers Dis; 2015; 44(3):729-44. PubMed ID: 25374110
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structure and mechanism of action of tau aggregation inhibitors.
    Cisek K; Cooper GL; Huseby CJ; Kuret J
    Curr Alzheimer Res; 2014; 11(10):918-27. PubMed ID: 25387336
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.
    Asih PR; Chatterjee P; Verdile G; Gupta VB; Trengove RD; Martins RN
    Neurodegener Dis Manag; 2014; 4(5):363-78. PubMed ID: 25405650
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations.
    Lashley T; Rohrer JD; Mead S; Revesz T
    Neuropathol Appl Neurobiol; 2015 Dec; 41(7):858-81. PubMed ID: 26041104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Systematic review of the relationship between amyloid-β levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease.
    Foley AM; Ammar ZM; Lee RH; Mitchell CS
    J Alzheimers Dis; 2015; 44(3):787-95. PubMed ID: 25362040
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
    J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Unique molecular signatures of Alzheimer's disease amyloid β peptide mutations and deletion during aggregate/oligomer/fibril formation.
    Poduslo JF; Howell KG
    J Neurosci Res; 2015 Mar; 93(3):410-23. PubMed ID: 25377128
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue.
    Lesne SE
    Swiss Med Wkly; 2014; 144():w14021. PubMed ID: 25375761
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new?
    Quartuccio N; Van Weehaeghe D; Cistaro A; Jonsson C; Van Laere K; Pagani M
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):344-54. PubMed ID: 25375229
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Investigation of (11)C-PiB equivocal PET findings.
    Hosokawa C; Ishii K; Hyodo T; Sakaguchi K; Usami K; Shimamoto K; Yamazoe Y; Hosono M; Hanada K; Ueda M; Saigo K; Murakami T
    Ann Nucl Med; 2015 Feb; 29(2):164-9. PubMed ID: 25373846
    [TBL] [Abstract][Full Text] [Related]  

  • 71. β-Amyloid peptides and amyloid plaques in Alzheimer's disease.
    Gouras GK; Olsson TT; Hansson O
    Neurotherapeutics; 2015 Jan; 12(1):3-11. PubMed ID: 25371168
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Integrative analysis of multi-dimensional imaging genomics data for Alzheimer's disease prediction.
    Zhang Z; Huang H; Shen D;
    Front Aging Neurosci; 2014; 6():260. PubMed ID: 25368574
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improvement in athletic performance as an early symptom of behavioral variant frontotemporal dementia.
    Ducharme S; Dickerson BC; Price BH
    J Neuropsychiatry Clin Neurosci; 2015; 27(2):e163-4. PubMed ID: 25923870
    [No Abstract]   [Full Text] [Related]  

  • 74. Amyloid imaging in dementia: contribution or confusion?
    Frey KA
    J Nucl Med; 2015 Mar; 56(3):331-2. PubMed ID: 25655624
    [No Abstract]   [Full Text] [Related]  

  • 75. A critical review of chronic traumatic encephalopathy.
    Iverson GL; Gardner AJ; McCrory P; Zafonte R; Castellani RJ
    Neurosci Biobehav Rev; 2015 Sep; 56():276-93. PubMed ID: 26183075
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia.
    Flanagan EP; Duffy JR; Whitwell JL; Vemuri P; Dickson DW; Josephs KA
    Neurocase; 2016; 22(1):55-9. PubMed ID: 25929342
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging.
    Zhang J
    J Neuroinflammation; 2015 May; 12():108. PubMed ID: 26022249
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with α-synuclein.
    Aoki N; Boyer PJ; Lund C; Lin WL; Koga S; Ross OA; Weiner M; Lipton A; Powers JM; White CL; Dickson DW
    Acta Neuropathol; 2015 Jul; 130(1):93-105. PubMed ID: 25962793
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Role of Coping Strategies in Psychological Outcomes for Frontotemporal Dementia Caregivers.
    Roche DClinPsy L; Croot K; MacCann C; Cramer B; Diehl-Schmid J
    J Geriatr Psychiatry Neurol; 2015 Sep; 28(3):218-28. PubMed ID: 26072312
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The evolution of preclinical Alzheimer's disease: implications for prevention trials.
    Sperling R; Mormino E; Johnson K
    Neuron; 2014 Nov; 84(3):608-22. PubMed ID: 25442939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.